EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Elexacaftor/Tezacaftor/Ivacaftor Effect on Bone Density and Body Composition: A Retrospective Analysis

Susanne Ursula Trost iD, Tasma Harindhanavudhi, Qi Wang, Anvitha Ankireddypalli, Azmi Simrah, Sreekant Avula, Amir Moheet

Pediatric Pulmonology · 2025

DOI: 10.1002/ppul.71280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Pulmonology, 2025. Verfasst von Susanne Ursula Trost und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Bone Density, Cystic Fibrosis, Body Composition, Aminophenols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The approval of cystic fibrosis transmembrane conductance regulator modulators elexacaftor/tezacaftor/ivacaftor (ETI), has significantly improved pulmonary function for people with cystic fibrosis (pwCF). However, the effects on CF‐related bone disease and body composition remain unclear.

Methods

This retrospective real‐world study examined adults with CF who received ETI treatment. Bone density and body composition were measured via dual‐energy X‐ray absorptiometry (DXA) 1.8 (SD 0.7) years before (preDXA) and 1.5 (SD 0.4) years after ETI initiation (postDXA1). In a subgroup, measurements were also available 4 (SD 0.6) years after initiation (postDXA2).

Results

The study included 74 pwCF, of whom 42% were female, with an average age of 38.9 (SD 9.3) years at ETI initiation. Bone density decreased significantly at the spine ( p = 0.02), left hip ( p < 0.01), and right hip ( p < 0.01) from pre‐ to postDXA1. No significant change in bone density was observed when comparing postDXA1 to postDXA2. Body composition analysis revealed significant increases in weight in both females ( p < 0.01) and males ( p < 0.01), as well as increases in fat mass in females ( p < 0.01) and males ( p < 0.01), without significant changes in lean mass ( p = 0.4).

Conclusions

Bone density declined significantly during the study period, with the most pronounced decline occurring in the first 1.5 years after ETI initiation. However, this decline appeared to stabilize in participants with longer follow‐up at 4 years post‐ETI treatment, suggesting potential bone‐protective effects with prolonged therapy. Body weight and fat mass increased early after ETI initiation, suggesting metabolic changes accompanying CFTR modulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone DensityCystic FibrosisBody CompositionAminophenolsBenzodioxolesQuinolonesIndolesPyridinesPyrrolidinesPyrazolesHumansFemaleRetrospective StudiesMaleAdultAbsorptiometry, PhotonDrug CombinationsMiddle AgedCystic Fibrosis Transmembrane Conductance Regulator

Stichwörter der Autor:innen

body compositionbone densitybone healthcystic fibrosiselexacaftor/tezacaftor/ivacaftorfat mass

Substanzen

AminophenolsBenzodioxolesQuinolonesivacaftorelexacaftorIndolestezacaftorDrug CombinationsPyridinesPyrrolidines

Autor:innen und Institutionen

  • Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA.
  • Clinical and Transitional Science Institute, University of Minnesota, Minneapolis, Minnesota, USA.

ORCID-Profile: Susanne Ursula Trost

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Trost, S. U., Harindhanavudhi, T., Wang, Q., Ankireddypalli, A., Simrah, A., Avula, S., & Moheet, A. (2025). Elexacaftor/Tezacaftor/Ivacaftor Effect on Bone Density and Body Composition: A Retrospective Analysis. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71280

Vancouver

Trost SU, Harindhanavudhi T, Wang Q, Ankireddypalli A, Simrah A, Avula S, et al. Elexacaftor/Tezacaftor/Ivacaftor Effect on Bone Density and Body Composition: A Retrospective Analysis. Pediatric Pulmonology. 2025. doi:10.1002/ppul.71280

BibTeX
@article{Trost2025,
  author = {Trost, Susanne Ursula and Harindhanavudhi, Tasma and Wang, Qi and Ankireddypalli, Anvitha and Simrah, Azmi and Avula, Sreekant and Moheet, Amir},
  title = {Elexacaftor/Tezacaftor/Ivacaftor Effect on Bone Density and Body Composition: A Retrospective Analysis},
  journal = {Pediatric Pulmonology},
  year = {2025},
  doi = {10.1002/ppul.71280}
}
Kostenlos starten →